Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877767 | 0.76 | LMNA (0.64) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL10720311 | 0.74 | DHFR (0.59) | LMNARAB9ASMN1; SMN2DHFRKMT2A | |
| SCHEMBL5821147 | 0.73 | ALDH1A1 (0.56) | LMNARAB9ASMN1; SMN2DHFRKMT2A | |
| SCHEMBL10123547 | 0.73 | LMNA (0.60) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL24000166 | 0.72 | ALDH1A1 (0.65) | LMNANPSR1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8132638 | 0.72 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12862543 | 0.72 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL10109757 | 0.72 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL11356595 | 0.72 | TP53 (0.50) | LMNASMN1; SMN2DHFRALDH1A1TSHR | |
| SCHEMBL6885992 | 0.72 | LMNA (0.77) | LMNANPSR1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3426640-A1 | PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | LMNA 1911/4885NPSR1 2611/4885RAB9A 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.